[{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"University of North Carolina","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Pacira BioSciences","highestDevelopmentStatusID":"6","companyTruncated":"Pacira BioSciences \/ Pacira BioSciences"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Hk Tainuo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Flexion Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Flexion Therapeutics \/ Hk Tainuo","highestDevelopmentStatusID":"15","companyTruncated":"Flexion Therapeutics \/ Hk Tainuo"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Flexion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Pacira BioSciences","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Pacira BioSciences"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Enekinragene Inzadenovec","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Enekinragene Inzadenovec","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Enekinragene Inzadenovec","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Enekinragene Inzadenovec","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Enekinragene Inzadenovec","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Genascence","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Series A Financing","leadProduct":"sc-rAAV2.5IL-1Ra","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Pacira BioSciences","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Pacira BioSciences","highestDevelopmentStatusID":"8","companyTruncated":"Pacira BioSciences \/ Pacira BioSciences"},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Humantakinogene Hadenovec","moa":"Interleukin-1 receptor antagonist protein (IL1RN)","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Flexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Flexion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Flexion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Humantakinogene Hadenovec","moa":"Interleukin-1 receptor antagonist protein (IL1RN)","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Flexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Flexion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Flexion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Kineta","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"KCP506","moa":"nACh receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Pacira BioSciences","highestDevelopmentStatusID":"6","companyTruncated":"Pacira BioSciences \/ Pacira BioSciences"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"GQ Bio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2025","type":"Acquisition","leadProduct":"GQ-501","moa":"PRG4","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Pacira BioSciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Pacira BioSciences","highestDevelopmentStatusID":"5","companyTruncated":"Pacira BioSciences \/ Pacira BioSciences"},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Funapide","moa":"SCN9A","graph1":"Neurology","graph2":"Preclinical","graph3":"Flexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Flexion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Flexion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Funapide","moa":"SCN9A","graph1":"Neurology","graph2":"Preclinical","graph3":"Flexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Flexion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Flexion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Depofoam Bupivacaine","moa":"Sodium channel","graph1":"Neurology","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Pacira BioSciences \/ Pacira BioSciences","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Pacira BioSciences"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Pacira BioSciences","highestDevelopmentStatusID":"9","companyTruncated":"Pacira BioSciences \/ Pacira BioSciences"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Depuy Synthes Sales","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Termination","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Depuy Synthes Sales","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Depuy Synthes Sales"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Premier","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Premier"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Eurofarma Laboratorios S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Eurofarma Laboratorios S.A","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Eurofarma Laboratorios S.A"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Suspension, Prolonged Release","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Suspension, Prolonged Release","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Podiatry","graph2":"Phase III","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension, Liposomal","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Pacira BioSciences","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Pacira BioSciences"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Pacira BioSciences","highestDevelopmentStatusID":"9","companyTruncated":"Pacira BioSciences \/ Pacira BioSciences"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Podiatry","graph2":"Phase III","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Pacira BioSciences","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Pacira BioSciences"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Undisclosed","graph2":"Phase III","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Pacira BioSciences","highestDevelopmentStatusID":"10","companyTruncated":"Pacira BioSciences \/ Pacira BioSciences"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Lotus Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FX301","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Lotus Clinical Research","highestDevelopmentStatusID":"6","companyTruncated":"Pacira BioSciences \/ Lotus Clinical Research"}]
Find Clinical Drug Pipeline Developments & Deals by Pacira BioSciences
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
